Monday, 20 Jul 2026
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • White
  • ScienceAlert
  • VIDEO
  • man
  • Trumps
  • Season
  • star
  • Years
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Why Citizens JMP Backed Viant in November After EBITDA Beat and ex‑TAC Strength
Economy

Why Citizens JMP Backed Viant in November After EBITDA Beat and ex‑TAC Strength

Last updated: December 9, 2025 7:35 pm
Share
Why Citizens JMP Backed Viant in November After EBITDA Beat and ex‑TAC Strength
SHARE

Viant Technology Inc. (NASDAQ:DSP) has been making waves as one of the best-performing small-cap tech stocks in the past three years. With a focus on privacy-centric, programmatic advertising, especially in the Connected TV space, Viant leverages proprietary identifiers and ViantAI to optimize targeting and measurement across the open internet.

Following the release of Viant’s Q3 earnings report on November 10, Citizens JMP’s Matthew Condon maintained a “Market Outperform” rating and slightly lowered the price target to $16 from $18. Despite the adjustment, Condon highlighted the strong quarter, noting that the contribution ex-TAC exceeded consensus estimates by around 2% and adjusted EBITDA surpassed the high end of guidance.

Viant reported revenue of $85.6 million, a 7% year-over-year increase, with a contribution ex-TAC of approximately $53 million, up 12% from the previous year. Adjusted EBITDA came in at around $16.0 million, a 9% increase year-over-year, with a 30% margin that exceeded midpoint guidance. Management attributed the outperformance to growing demand in the Connected TV sector, broader adoption of its Household ID / IRIS_ID addressability stack, and new brand wins. Excluding political spend and a seasonal advertiser that transitioned off-platform due to a merger, revenue grew by approximately 19% and contribution ex-TAC by 22%.

Looking ahead, Viant provided guidance for Q4, projecting a contribution ex-TAC of $62–$64 million and adjusted EBITDA of $22.5–$23.5 million. The company remains optimistic about its future prospects, particularly in the rapidly evolving ad-tech landscape.

While Viant Technology Inc. shows promise as an investment opportunity, some investors may prefer to explore other AI stocks with potentially greater upside potential and lower downside risk. For those interested in uncovering undervalued AI stocks poised to benefit from current market trends, a free report on the best short-term AI stock may offer valuable insights.

See also  Disney to invest $1bn in OpenAI

In conclusion, Viant Technology Inc. continues to demonstrate its strength and resilience in the competitive tech industry. With a focus on innovative solutions and strategic partnerships, the company is well-positioned for continued growth and success in the evolving digital advertising landscape.

TAGGED:backedbeatCitizensEBITDAexTACJMPNovemberstrengthViant
Share This Article
Twitter Email Copy Link Print
Previous Article RFK, Jr., Questions Safety of Approved RSV Shots for Babies RFK, Jr., Questions Safety of Approved RSV Shots for Babies
Next Article Surgeon allegedly shoved crushed abortion pills into pregnant girlfriend’s mouth while she slept Surgeon allegedly shoved crushed abortion pills into pregnant girlfriend’s mouth while she slept
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *


The reCAPTCHA verification period has expired. Please reload the page.

Popular Posts

How A 60-Year-Old Drug Developer Built $4.4 Billion Krystal Biotech To Treat ‘Butterfly Skin Disease’

Suma Krishnan: The Visionary Behind Krystal Biotech's Success By Amy Feldman, Forbes Staff Longtime drug…

August 2, 2025

Real-Life Clown Insists Trump Is A Buffoon, Not A Clown

Oops. Next op-ed could be a Space Cadet writing about how insulted he is to…

July 11, 2025

How Paris Saint-Germain made the Champions League final and got better without Kylian Mbappe

Paris Saint-Germain has booked their spot in the Champions League final after defeating Arsenal 2-1,…

May 8, 2025

15+ Effective Assessment Strategies for Teachers to Try

25 Assessments are essential communication tools between educators and learners. They clarify teachers' expectations regarding…

December 29, 2025

Joint Statement on a Framework for a United States – Switzerland – Liechtenstein Agreement on Fair, Balanced, and Reciprocal Trade

Framework for Fair Trade Negotiations Among the U.S., Switzerland, and Liechtenstein In a significant move…

November 14, 2025

You Might Also Like

Jensen Huang’s staggering  trillion bet shifts Nvidia
Economy

Jensen Huang’s staggering $4 trillion bet shifts Nvidia

July 20, 2026
Where are Americans saving the most — and least?
Economy

Where are Americans saving the most — and least?

July 20, 2026
Should You Buy Palantir Technologies Stock While It’s Trading Below 0?
Economy

Should You Buy Palantir Technologies Stock While It’s Trading Below $140?

July 20, 2026
James Hardie Industries plc (JHX) Recovered Following Easing Middle East Conflict and Strong Outlook
Economy

James Hardie Industries plc (JHX) Recovered Following Easing Middle East Conflict and Strong Outlook

July 20, 2026
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?